"The classic clinical feature of myasthenia gravis is fatigueable muscle weakness, that is, weakness that is worse with activity and improves with rest 2. Myasthenia gravis can present with either ocular (ocular myasthenia gravis) or generalised (generalised myasthenia gravis) phenotypes, which depends on patient age, autoantibody serostatus, and presence/absence of thymic disease 30."
"The classic clinical feature of myasthenia gravis is fatigueable muscle weakness, that is, weakness that is worse with activity and improves with rest 2. Myasthenia gravis can present with either ocular (ocular myasthenia gravis) or generalised (generalised myasthenia gravis) phenotypes, which depends on patient age, autoantibody serostatus, and presence/absence of thymic disease 30."
"MuSK antibody myasthenia gravis 32,33,35"
"MuSK (muscle-specific kinase) antibody:"
"Lambert-Eaton myasthenic syndrome"
"Otherwise, myasthenia gravis generally does not have any particular radiographic features. In patients with MuSK antibody myasthenia gravis in particular, non-specific muscle atrophy with fatty replacement may be seen on cross-sectional imaging in chronically affected muscles (e.g. in the tongue, extraocular muscles) 15,16,36,37. If enlargement of extraocular muscles is noted, then concurrent thyroid-associated orbitopathy should be suspected, which can rarely co-occur in patients with AChR antibody myasthenia gravis 37."
Expected headings
"Associations"
"thyroiditis: most commonly Graves disease; Hashimoto thyroiditis is rare 10"
"In AChR antibody myasthenia gravis, initial pharmacological treatment is symptomatic therapy with acetylcholinesterase inhibitors (e.g. pyridostigmine 31), however, many patients will require immunosuppression as the disease progresses. Immunosuppression options include corticosteroids, oral steroid-sparing agents (e.g. azathioprine, mycophenolate mofetil), and other immunosuppressive agents (e.g. intravenous immunoglobulin, rituximab, zilucoplan, eculizumab, efgartigimod, rozanolixizumab) and techniques (e.g. plasmapheresis) 2,6,17,23,24,32."
"In AChR antibody myasthenia gravis, initial pharmacological treatment is symptomatic therapy with acetylcholinesterase inhibitors (e.g. pyridostigmine 31), however, many patients will require immunosuppression as the disease progresses. Immunosuppression options include corticosteroids, oral steroid-sparing agents (e.g. azathioprine, mycophenolate mofetil), and other immunosuppressive agents (e.g. intravenous immunoglobulin, rituximab, zilucoplan, eculizumab, efgartigimod, rozanolixizumab) and techniques (e.g. plasmapheresis) 2,6,17,23,24,32."
"There are a number of medications and other substances that can potentially make myasthenia gravis worse and thus should be avoided or used with caution in affected patients, including, but not limited to 2,19:"
"mitochondrial diseases (e.g. chronic progressive external ophthalmoplegia)"